Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40


Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy.

Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, Ding H, Nan Y, Jiang W, Wang T, Liu H, Ou X, Wee A, Theise ND, Jia J, You H.

Sci Rep. 2018 Feb 14;8(1):2989. doi: 10.1038/s41598-018-21179-2.


Histopathological evaluation of liver fibrosis and cirrhosis regression.

Lo RC, Kim H.

Clin Mol Hepatol. 2017 Dec;23(4):302-307. doi: 10.3350/cmh.2017.0078. Epub 2017 Dec 20. Review.


Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling.

Sato-Matsubara M, Matsubara T, Daikoku A, Okina Y, Longato L, Rombouts K, Thuy LTT, Adachi J, Tomonaga T, Ikeda K, Yoshizato K, Pinzani M, Kawada N.

J Biol Chem. 2017 Nov 17;292(46):18961-18972. doi: 10.1074/jbc.M117.793794. Epub 2017 Sep 15.


Can a fibrotic liver afford epithelial-mesenchymal transition?

Munker S, Wu YL, Ding HG, Liebe R, Weng HL.

World J Gastroenterol. 2017 Jul 14;23(26):4661-4668. doi: 10.3748/wjg.v23.i26.4661.


Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy.

Procopet B, Berzigotti A.

Gastroenterol Rep (Oxf). 2017 May;5(2):79-89. doi: 10.1093/gastro/gox012. Epub 2017 Apr 17. Review.


The Treatment of Hepatic Fibrosis: Reversal of the Underlying Disease Process.

Servin-Abad L, Schiff ER.

Gastroenterol Hepatol (N Y). 2006 Nov;2(11):819-825.


Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C.

Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A.

World J Hepatol. 2017 Mar 8;9(7):352-367. doi: 10.4254/wjh.v9.i7.352. Review.


On beyond staging and grading: Liver biopsy evaluation in a posttreatment world.

Kleiner DE.

Hepatology. 2017 May;65(5):1432-1434. doi: 10.1002/hep.29111. Epub 2017 Mar 30. No abstract available.


Natural regression of fibrosis in chronic hepatitis B.

Ohkoshi S, Hirono H, Watanabe K, Hasegawa K, Kamimura K, Yano M.

World J Gastroenterol. 2016 Jun 28;22(24):5459-66. doi: 10.3748/wjg.v22.i24.5459. Review.


Magnetization-tagged MRI is a simple method for predicting liver fibrosis.

Kim KE, Park MS, Chung S, An C, Axel L, Ergashovna RG.

Clin Mol Hepatol. 2016 Mar;22(1):140-5. doi: 10.3350/cmh.2016.22.1.140. Epub 2016 Mar 28.


Liver pathology of hepatitis C, beyond grading and staging of the disease.

Dhingra S, Ward SC, Thung SN.

World J Gastroenterol. 2016 Jan 28;22(4):1357-66. doi: 10.3748/wjg.v22.i4.1357. Review.


Four-dimensional flow magnetic resonance imaging in cirrhosis.

Stankovic Z.

World J Gastroenterol. 2016 Jan 7;22(1):89-102. doi: 10.3748/wjg.v22.i1.89. Review.


Stem cell-based regenerative opportunities for the liver: State of the art and beyond.

Tsolaki E, Yannaki E.

World J Gastroenterol. 2015 Nov 21;21(43):12334-50. doi: 10.3748/wjg.v21.i43.12334. Review.


Idiopathic Noncirrhotic Portal Hypertension: An Appraisal.

Lee H, Rehman AU, Fiel MI.

J Pathol Transl Med. 2016 Jan;50(1):17-25. doi: 10.4132/jptm.2015.09.23. Epub 2015 Nov 11. Review.


Plumbagin Ameliorates CCl 4 -Induced Hepatic Fibrosis in Rats via the Epidermal Growth Factor Receptor Signaling Pathway.

Chen S, Chen Y, Chen B, Cai YJ, Zou ZL, Wang JG, Lin Z, Wang XD, Fu LY, Hu YR, Chen YP, Chen DZ.

Evid Based Complement Alternat Med. 2015;2015:645727. doi: 10.1155/2015/645727. Epub 2015 Oct 15.


Study on the Antifibrotic Effects of Recombinant Shark Hepatical Stimulator Analogue (r-sHSA) in Vitro and in Vivo.

Wang Y, Zhang X, Yang Y, Yang X, Ye B.

Mar Drugs. 2015 Aug 18;13(8):5201-18. doi: 10.3390/md13085201.


Two sides of one coin: massive hepatic necrosis and progenitor cell-mediated regeneration in acute liver failure.

Weng HL, Cai X, Yuan X, Liebe R, Dooley S, Li H, Wang TL.

Front Physiol. 2015 Jun 16;6:178. doi: 10.3389/fphys.2015.00178. eCollection 2015. Review.


Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients.

Papachrysos N, Hytiroglou P, Papalavrentios L, Sinakos E, Kouvelis I, Akriviadis E.

Ann Gastroenterol. 2015 Jul-Sep;28(3):374-378.


Idiopathic non-cirrhotic portal hypertension: a review.

Schouten JN, Verheij J, Seijo S.

Orphanet J Rare Dis. 2015 May 30;10:67. doi: 10.1186/s13023-015-0288-8. Review.


Reversibility and heritability of liver fibrosis: Implications for research and therapy.

Atta HM.

World J Gastroenterol. 2015 May 7;21(17):5138-48. doi: 10.3748/wjg.v21.i17.5138. Review.

Supplemental Content

Support Center